n.achebe
TL2 Moderator · Verona
Contributes reviews on supplier material. Based in Verona.
Joined 24 December 2024 · last posted 5d
78Posts here
3Topics
1Solutions
262Likes received
135Likes given
21Badges
129Days visited
1.2kPosts read
Recent activity
Full stream-
Revisiting: Can a home kit substitute for a laboratory report? A careful no Replied, post #55 · Analytics › Home & field testing · 23 Jul 2026 · 0 likes For anyone arriving from a search: the marked solution above is the direct answer, and the replies underneath it add the caveats that make it safe to use.
-
A site rotation scheme that is easy enough to actually follow — a second dataset Replied, post #7 · Practice › Administration · 15 Jul 2026 · 7 likes Practical note that does not fit anywhere else. Whatever you conclude from this topic, write down what you did and when. The single most useful thing in your own…
-
Follow-up: How compounding permissions changed when supply normalised Replied, post #11 · Sourcing › Regulatory · 11 Jul 2026 · 8 likes I disagree with the reply above, and I think the disagreement is substantive rather than terminological. The distinction being drawn does not survive when you look at…
-
Named, unnamed and unspecified impurities as regulatory categories — the long version Replied, post #67 · Analytics › Impurities & related substances · 11 Jul 2026 · 29 likes On post #63 — agreed on the reasoning, with one qualification. Truncation products: fragments from incomplete synthesis or from degradation. They elute quite…
-
Pages past their review date, listed — does this still hold? Replied, post #31 · Meta › Wiki maintenance · 30 Jun 2026 · 5 likes Maintainer handovers: if a page's maintainer is inactive and needs a new one, discussing that here can facilitate the transition.
-
Mobile reading experience on long topics Replied, post #2 · Meta › Site feedback · 24 Jun 2026 · 19 likes the opening post answers the question as asked. The question underneath it is different. Moderation decisions: if you disagree with a moderation decision, raising it…
-
An appeal that succeeded, with the letter structure Replied, post #10 · Access › Insurance & coverage · 22 Jun 2026 · 0 likes Prior authorisation: pre-approval requirements and how to satisfy them. Most denials cite specific criteria. Understanding the criterion is the first step in satisfying…
-
Pooling trials with different estimands Replied, post #31 · Evidence › Meta-analyses · 17 Jun 2026 · 25 likes Fixed-effects versus random-effects models: fixed-effects assumes all studies are estimating the same thing and variation is sampling error. Random-effects assumes…
-
Primary endpoint hierarchies and why order matters — one year on Replied, post #16 · Evidence › Trials · 15 Jun 2026 · 3 likes Multiplicity and multiple comparisons: if a trial tests many hypotheses, the chance of a false positive on at least one by random chance increases. This is why…
-
Journal club: what we got wrong in an earlier session Started this topic · Evidence › Journal club · 11 Jun 2026 · 13 likes On the subject in the title: Journal club: what we got wrong in an earlier session Working notes rather than a conclusion. Session topic: SURMOUNT-1 ( N Engl J Med ,…
-
Does dual agonism explain the effect size, or is it dose? Replied, post #23 · Compounds › Tirzepatide · 8 Jun 2026 · 0 likes SURPASS-2 compared tirzepatide with semaglutide 1.0 mg, the licensed diabetes dose at that time. It did not compare with semaglutide 2.4 mg, the highest approved dose.…
-
Journal club: STEP 1 and the treatment-policy estimand — does this still hold? Replied, post #26 · Evidence › Journal club · 24 May 2026 · 0 likes TRIUMPH (ongoing): Retatrutide phase 3. No results yet. Nothing should be attributed to it because it has not finished. When it does, this discussion will return to it.